Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of Eryngiolide A in medicine for resisting tubercle bacillus

An anti-tuberculosis and drug technology, applied in the direction of antibacterial drugs, etc., to achieve the effects of strong tuberculosis inhibitory activity, expanded types, and broad application prospects

Inactive Publication Date: 2013-05-29
吴俊华
View PDF1 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, due to the irregular treatment and management of tuberculosis patients, irregular chemotherapy and abuse of anti-tuberculosis drugs, the drug resistance of tuberculosis is becoming more and more serious, and the change of drug resistance tends to be multi-drug resistance at the same time. great difficulty at work

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of Eryngiolide A in medicine for resisting tubercle bacillus
  • Application of Eryngiolide A in medicine for resisting tubercle bacillus
  • Application of Eryngiolide A in medicine for resisting tubercle bacillus

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0016] Embodiment 1: Preparation of the compound Eryngiolide A tablet involved in the present invention:

[0017] Take 20 grams of compound Eryngiolide A, add 180 grams of conventional excipients for tablet preparation, mix well, and make 1000 tablets with a conventional tabletting machine.

Embodiment 2

[0018] Embodiment 2: the preparation of the compound Eryngiolide A capsule of the present invention:

[0019] Get 20 grams of compound Eryngiolide A, add conventional auxiliary materials for preparing capsules such as 180 grams of starch, mix well, and pack into capsules to make 1000 tablets.

[0020] The following pharmacodynamic experiments will further illustrate its drug activity.

[0021] The present invention will be further described below in conjunction with specific examples, but the specific examples do not limit the present invention in any form.

experiment example 1

[0022] Experimental Example 1 Determination of the Absolute Concentration of Eryngiolide A Against Bacillus Calmette-Guerin (BCG) by the Solid Medium Dilution Method

[0023] Scrape the BCG culture from the slant, add it to 3ml Middlebrook7H9 broth medium, add a small amount of glass beads, tighten the test tube cap, vibrate and grind vigorously on the vortex oscillator, and compare it with the standard McFarland turbidimetric tube (MacFarland No.1 ) turbidity, that is, to prepare 1mg / ml bacillus Calmette-Guerin (BCG) bacterial suspension.

[0024] Make Eryngiolide A into a high-concentration stock solution with DMSO, dilute the stock solution to the required concentration with 5% Tween-80 sterile ultrapure water, and add the diluted Eryngiolide A to 4ml Middlebrook7H11 agar medium according to the required dose (The medium has been sterilized by high pressure steam at 121°C for 15 minutes, cooled to 50~55°C), mixed evenly to make Eryngiolide A, the concentrations are 6.0 ug / m...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses an application of Eryngiolide A in preparation of a medicine for resisting tubercle bacillus. The Eryngiolide A has outstanding inhibitory activity on the tubercle bacillus and very good application prospect by aiming at the existing conditions that current tuberculosis morbidity is high and tuberculosis morbidity and mortality shows a rising trend due to the generation of multiple mycobacterium tuberculosis medicine-resistant strains. The application of the Eryngiolide A in preparation of the medicine for resisting the tubercle bacillus is firstly disclosed because a skeleton type belongs to a fire-new skeleton type and the inhibitory activity of the Eryngiolide A on the tubercle bacillus is inconceivably high; and the Eryngiolide A has outstanding substantiality characteristic without possibility of any inspiration given by other compounds and obviously achieves the outstanding progress by being used for preventing and treating tubercle bacillus infection.

Description

technical field [0001] The invention relates to the application field of pharmaceutical compounds, in particular to the application of Eryngiolide A in the preparation of anti-tuberculosis drugs. Background technique [0002] In recent years, the incidence of tuberculosis in the world has shown an increasing trend. According to the World Health Organization (WHO) estimates, the population infected by Mycobacterium tuberculosis (MTB) accounts for one-third of the world's population, of which 5-10% Infected people become TB patients. There are 1.3 million cases of active tuberculosis patients in my country every year, including about 600,000 cases of infectious tuberculosis, and about 600,000 cases of infectious tuberculosis. It is one of the countries with a high burden of tuberculosis in the world. [0003] Since the advent of anti-tuberculosis drugs one after another, the treatment of tuberculosis has played an epoch-making change. However, due to the irregular treatment ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/365A61P31/06
Inventor 李丽丽邱翔宇冯怡吴俊华
Owner 吴俊华
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com